Meibang's net profit in 2022 is 145 million yuan, and it will promote the integration of the industrial chain of its two major projects

On April 20, Meibang released the annual report for 2022. During the reporting period, the company achieved an operating revenue of 90,0445,600 yuan, an increase of 7.54% compared with the same period last year. Net profit attributable to the shareholders of the parent company was 14,508,300 yuan, an increase of 15.38% over the same period last year. Net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was 131,483,900 yuan, an increase of 18.39% over the same period last year. Earnings per share was 1.07 yuan, down 6.14% from the same period last year. Excluding non-recurring gains and losses, earnings per share were 0.97 yuan, down 3.96% from the same period last year; Total assets: 1,56,494,800 yuan, net assets attributable to shareholders of the listed company: 1,086,352,700 yuan.

The announcement shows that in 2022, the company has achieved good business performance through "adhering to the innovation and development of the main business, accurately grasping the market opportunities, enriching the product line to ensure customer demand, and deepening customer cooperation.

promote the construction of key projects and promote the advantages of integrated development of industrial chains

During the reporting period, under the guidance of the high-quality development strategy, the company vigorously promoted the construction of two key projects in order to ensure national food security and stabilize the supply of pesticide demand. One was the construction project of production line of new green pesticide formulation and 30,000 t/a water-soluble fertilizer in Weinan.

Second, the construction project of pesticide technical and intermediate production line with  20,000 t/a was launched in Weinan. After the completion of the project, the whole industrial chain of pesticide technical formulation will be driven by the integration, so as to enhance the sustainable competitiveness of the enterprise. On the other hand, with the release of the capacity of active drug in the future, the company will also increase the profit growth point, and the company's industrialization and scale advantage will be more significant.

Scientific research and innovation support display effect, enhance the core competitiveness of the market

Research and development expenses in 2022 amounted to RMB 80,043,200, an increase of 25.45% over the same period of last year, accounting for 8.83% of the operating revenue. By the end of the report period, the company has obtained 1,089 pesticide certificates, ranking in the forefront of the industry, with strong product qualification advantages. At the same time, accurately grasp the market trend, increase the incremental market development of high value-added pesticide products, the company's market competitiveness has been further improved.